Journal: Bioscience Reports

Article Title: Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells

doi: 10.1042/BSR20240752

Figure Lengend Snippet: ( A ) SeChry@PURE G4 -LA 24 nanoformulation. Chemical structures of the generation four polyurea dendrimer lactate conjugate and encapsulated SeChry molecules. A549, H292, PC-9, H1975, H522, H596 and BEAS-2B cells were exposed to empty nanoparticles (PURE G4 -LA) or SeChry@PURE G4 -LA 24 for 48 h. Percentage of cell death analyzed by flow cytometry using Annexin V and PI in ( B ) PURE G4 -LA 24 -treated cells and ( C ) Sechry@PURE G4 -LA 24 -treated cells. ( D ) EC50 curves and values for SeChry@PURE G4 -LA. Data are represented as mean ± SD. * P <0.5, ** P <0.01, *** P <0.001, **** P <0.0001 (one-way ANOVA with Tukey’s multiple comparisons test was used).

Article Snippet: Normal human bronchial epithelium cell line BEAS-2B (CRL-3588™, ATCC) was also used.

Techniques: Flow Cytometry

Journal: Bioscience Reports

Article Title: Metabolic profiling and combined therapeutic strategies unveil the cytotoxic potential of selenium-chrysin (SeChry) in NSCLC cells

doi: 10.1042/BSR20240752

Figure Lengend Snippet: Analysis of the expression profiles of MCT1/SLC16A1 in normal lung tissue and primary carcinomas in ( A ) LUAD and ( B ) LUSC and MCT4/SLC16A3 in ( C ) LUAD and ( D ) LUSC extracted from the TCGA database. A two-tailed unpaired Student’s t -test with Welch’s correction was used. ( E ) Cells were kept in control conditions and immunofluorescence analysis showed that all cell lines express MCT1. Nuclei were stained with DAPI (blue). The white bars scale means 20 μm. The cytotoxic response to SeChry@PURE G4 -LA 24 combined with MCT1 or MCT4 inhibitors was evaluated. Cells were incubated overnight with the MCT1 inhibitor AZD3965 and/or the MCT4 inhibitor AZD0095 and the following day, they were treated with SeChry@PURE G4 -LA 24 at the determined LC50 concentration. Percentage of cell death analyzed by flow cytometry using Annexin V and PI in ( F ) A549, ( G ) H292, ( H ) PC-9 and ( I ) BEAS-2B cells. Data are represented as mean ± SD. * P <0.5, ** P <0.01, *** P <0.001, **** P <0.0001 (one-way ANOVA with Tukey’s multiple comparisons test was used). The effect of the combination of SeChry@PURE G4 -LA 24 with the EGFR inhibitor gefitinib was evaluated. Cells, ( J ) A549, ( K ) H292, ( L ) PC-9, ( M ) H522, ( N ) H596, ( O ) H1975, and ( P ) BEAS, were incubated overnight with gefitinib and the following day, they were treated with SeChry@PURE G4 -LA 24 at the determined LC50 concentration. Data are represented as mean ± SD. * P <0.5, ** P <0.01, *** P <0.001, **** P <0.0001 (one-way ANOVA with Tukey’s multiple comparisons test was used).

Article Snippet: Normal human bronchial epithelium cell line BEAS-2B (CRL-3588™, ATCC) was also used.

Techniques: Expressing, Two Tailed Test, Control, Immunofluorescence, Staining, Incubation, Concentration Assay, Flow Cytometry